- Home
- FWRG vs CERT Comparison
FWRG vs CERT Comparison
Compare FWRG & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWRG | CERT |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.9M | 860.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FWRG | CERT |
|---|---|---|
| Price | $11.22 | $4.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $20.46 | $11.67 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.33 | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,222,501,000.00 | $418,838,000.00 |
| Revenue This Year | $15.58 | $4.18 |
| Revenue Next Year | $12.81 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.34 | 8.75 |
| 52 Week Low | $10.09 | $4.59 |
| 52 Week High | $19.53 | $13.88 |
Technical Indicators
Market Signals| Indicator | FWRG | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 23.11 |
| Support Level | $10.09 | N/A |
| Resistance Level | $12.93 | $6.47 |
| Average True Range (ATR) | 0.57 | 0.34 |
| MACD | -0.20 | -0.18 |
| Stochastic Oscillator | 19.49 | 0.00 |
Price Performance
Historical ComparisonAbout FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. The company generates revenues from Restaurant sales and Franchise revenues. It generates maximum revenue from Restaurant sales.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.